Navigation Links
VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Date:5/15/2008

esults to differ materially from current expectations include, but are not limited to:

-- our ability to obtain necessary financing;

-- our ability to control our operating expenses;

-- our ability to recruit and enroll patients for the ACS and FDG-PET

clinical trials;

-- failure to obtain sufficient data from enrolled patients that can be

used to evaluate VIA-2291, thereby impairing the validity or

statistical significance of our clinical trials;

-- our ability to successfully complete our clinical trials of VIA-2291

on expected timetables and the outcomes of such clinical trials;

-- complexities in designing and implementing cardiovascular clinical

trials using histological examinations, measurement of biomarkers,

medical imaging and atherosclerotic plaque bioassays;

-- the results of our clinical trials, including without limitation, with

respect to the safety and efficacy of VIA-2291;

-- the outcome of any legal proceedings;

-- our ability to obtain necessary FDA approvals;

-- our ability to successfully commercialize VIA-2291;

-- our ability to obtain and protect our intellectual property related to

our product candidates;

-- our potential for future growth and the development of our product

pipeline;

-- our ability to form and maintain collaborative relationships to

develop and commercialize our product candidates;

-- general economic and business conditions; and

-- the other risks described under Item IA "Risk Factors" in our Annual

Report on Form 10-K for the fiscal year ended December 31, 2007 on

file with the SEC.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 /CNW/ - On Aug. 20, ... , the Canadian Medical Association (CMA) voted on and ... plant material, including medicinal cannabis. Bedrocan Cannabis Corp., a ... of the CMA motion. The CMA is ... hazards associated with smoking any plant material, including medicinal ...
(Date:8/22/2014)... COLUMBUS, Ohio , Aug. 22, 2014 MC ... Devices Inc. (MID), a Columbus, OH ... to distribute the FloShield laparoscopic and robotic visualization system in ... will be approved for sale in Japan ... has a long-time experience and an extensive product portfolio in ...
(Date:8/22/2014)... Research and Markets has announced ... Respirators Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Global and Chinese Particulate Respirators Industry Report 2014 2
... 2011 Quest Diagnostics Incorporated (NYSE: DGX ... and services, announced that it is scheduled to speak ... York City. The presentation is scheduled for Tuesday, September ... The presentation will be webcast live during the conference ...
... Sept. 8, 2011 Spherix Incorporated ... in biotechnology for therapy in diabetes, metabolic syndrome ... consulting services to food, supplement, biotechnology and pharmaceutical ... SPX-106, achieved statistically significant reductions in VLDL and ...
Cached Medicine Technology:SPX-106T Treatment Yields Significant Reductions in Serum VLDL and LDL Cholesterol in Mice 2SPX-106T Treatment Yields Significant Reductions in Serum VLDL and LDL Cholesterol in Mice 3
(Date:8/23/2014)... August 23, 2014 On Monday, August ... a data breach suffered by Community Health Systems, ... compromise of 4.5 million records containing Personally Identifiable Information ... According to Mandiant, who was engaged to investigate the ... an advanced group of cyber attackers based in China, ...
(Date:8/23/2014)... 2014 Pixel Film Studios, a leader of ... release of ProIntro Vol.3, a customizable title tool for ... tile just by dragging ProIntro Vol.3 in their timeline" says ... a definite time saver and i think our users will ... beautifully designed titles made with Final Cut Pro X users ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 Teen drug ... Carolina. It’s no different in Wilmington, NC. Substance abuse ... are falling victim to drug and alcohol dependency in ... are looking to overcome substance abuse, but don’t know ... adolescent treatment facility can be a challenge because most ...
(Date:8/22/2014)... The IT manager of Top10BestSEOHosting.com is ... several years. He has recently announced that GoDaddy ( ... in 2014. , GoDaddy is a popular supplier of ... great hosting solutions at affordable rates. It offers three ... hosting plans depend on the length of the contract. ...
(Date:8/22/2014)... Today, Zane Benefits, the #1 Online ... Health Plans. , According to Zane Benefits, employers are ... lower the cost of healthcare without reducing coverage for ... however, can be confusing. , The new guide contains ... main types of ABHPs. It also explains the ...
Breaking Medicine News(10 mins):Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2
... News) -- The prevalence of psoriasis -- a chronic, inflammatory ... and obese kids, researchers have found. The Kaiser ... , also found that teens with psoriasis (regardless of their ... risk for heart disease. "This study suggests a ...
... 20 (HealthDay News) -- For the average listener, the ... speaker,s sexual orientation, a new study finds. "I,m not ... vowel," study lead author Erik C. Tracy, a cognitive psychologist ... the American Institute of Physics. "Other researchers have done various ...
... , FRIDAY, May 20 (HealthDay News) -- All ... to 11 years old, according to new guidelines from the ... with a family history of premature cardiovascular disease or elevated ... as early as age 2. "It,s important that people ...
... Dr. Jeffrey M. Trent, F.A.C.M.G., a nationally recognized ... has been appointed Foreign Trade Counselor of Luxembourg in ... and Research Director of the Translational Genomics Research Institute ... Grand Rapids, Michigan. Both non-profit biomedical research institutes study ...
... News) -- Though a new study suggests that a dietary ... develop preeclampsia, the jury is still out over whether it ... it yet. Preeclampsia is a pregnancy complication ... hypertension. It affects about 5 percent of first pregnancies. ...
... SESSION I / Monday, May 23 / 8 ... Acute Coronary Syndrome Patients in Real World Clinical Practice: Observations ... Bhandary D2, Stephenson JJ1, Gold A2, Fu AC1, Kern DM1, ... SESSION II / Tuesday, May 24 / 8 ...
Cached Medicine News:Health News:Study Sees Link Between Psoriasis, Obesity in Kids 2Health News:Straight or Gay? Vowels in Speech May Give it Away 2Health News:Experts Say Cholesterol Screenings Should Start in Childhood 2Health News:TGen/VARI president Dr. Jeffrey Trent appointed Foreign Trade Counselor by Luxembourg 2Health News:Study Suggests Supplement May Protect Against Preeclampsia 2Health News:HealthCore presents ISPOR poster sessions 2
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: